WEXFORD, Pa. - Nov. 16, 2018 - eTradeWire -- COEPTIS PHARMACEUTICALS SIGNS MULTI-PRODUCT DEVELOPMENT AGREEMENT WITH VICI HEALTH SCIENCES
Wexford, PA, November 16, 2018– Coeptis Pharmaceuticals, Inc announced today that it has entered into a multi-product agreement with Vici Health Sciences under which Coeptis and Vici expect to develop and commercialize several generic and 505(b)(2) products. Under the terms of the agreement, Vici will develop the products in their state-of-the-art facility located in Elkridge, MD and tech-transfer to a contract manufacturing organization for commercial supply. Coeptis will market and distribute the products throughout the US.
Dave Mehalick, CEO of Coeptis stated: “We are thrilled to begin the development of these products with Vici. As Coeptis continues through a period of immense growth, partners such as Vici will remain vital to our success. Vici is a great company with a proven track record of success in formulating a variety of simple to complex dosage forms. In the future, we hope to expand our agreement with Vici by adding additional products which helps to create value for both companies”.
Dr. Anish Dhanarajan, CEO of Vici stated: “This partnership opens up tremendous opportunities for both companies. Vici will focus on its core capability of R&D, while Coeptis will leverage its strength in product commercialization. Together, we will bring cost-effective and innovative medicine to patients in need.”
About Coeptis Pharmaceuticals:
Coeptis Pharmaceuticals, Inc is a privately held pharmaceutical company engaged in all phases of the pharmaceutical business. Headquartered near Pittsburgh, PA, the company holds a robust pipeline of niche, high-barrier generic and 505(b)(2) products across various therapeutic categories.
About Vici Health Sciences:
Vici Health Sciences, LLC is a technology-based private company focused on the research and development of innovative and high-quality medicine. Working with commercialization partners, Vici is currently developing an exciting pipeline of high value generic and 505(b)(2) oral and parenteral pharmaceutical products to serve unmet patient needs.